The agency had concerns the implant’s “neural lace” could trek into the soft tissue of the brain, that the chip could overheat, the battery might fail, and that removal could damage the brain, the news outlet wrote, citing Reuters reporting.
“This technology in all its forms represents a potential breakthrough for people with debilitating conditions, but putting the foreign matter, let alone a great deal of it, into the brain is fundamentally dangerous,” the story noted. “A company that wants to pursue such lofty applications as restoring sight and mobility must first prove that the implants are safe at a basic level, and that is what the FDA is reportedly asking.”
Last month, CNBC reported that Neuralink was under federal investigation for mishandling contaminated devices that had been tested on primates.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.